PNC-27
32-residue peptide combining a p53 HDM-2-binding domain with a cell-penetrating leader; kills cancer cells in laboratory studies; no human trial; not a cancer treatment.
60-Second Scientific Briefing
PNC-27 is a 32-amino-acid laboratory peptide that combines part of the p53 protein with a cell-penetrating sequence. It is studied for killing cancer cells in the laboratory and is not a cancer treatment. All published studies are laboratory (cell) studies, including cervical, other solid-tumour and blood cancer cell lines. Not approved by the US FDA or any other regulator; it is a research compound.
What is PNC-27?
Pharmacological Classification & Molecular IdentityPNC-27 is a 32-amino-acid laboratory peptide that combines part of the p53 protein with a cell-penetrating sequence. It is studied for killing cancer cells in the laboratory and is not a cancer treatment. [1] Biomedicines, 2022 ↗
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingReceptor Selectivity: In laboratory studies it binds HDM-2 protein found on the membrane of cancer cells and forms pores that lyse the cells, while sparing normal cells that lack membrane HDM-2. [1] Biomedicines, 2022 ↗
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNot approved by the US FDA or any other regulator; it is a research compound. [1] Biomedicines, 2022 ↗
PNC-27 is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesNo human clinical trial has been published. Biomedicines 2022: structural and microscopy studies showed PNC-27 binding membrane HDM-2 and forming pores in cancer cells. Ann Clin Lab Sci 2025: it killed squamous cervical cancer cells but not untransformed cervical cells in culture. [1] Ann Clin Lab Sci, 2025 ↗ [2] Biomedicines, 2022 ↗
Clinical Evidence
No human clinical trial has been published. Biomedicines 2022: structural and microscopy studies showed PNC-27 binding membrane HDM-2 and forming pores in cancer cells. Ann Clin Lab Sci 2025: it killed squamous cervical cancer cells but not untransformed cervical cells in culture.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesThere are no human safety data. Laboratory selectivity for cancer cells does not establish safety in the body. [1] Biomedicines, 2022 ↗
Whether it has any effect or is safe in people is unknown; it must not be presented or used as a cancer treatment. [1] Biomedicines, 2022 ↗
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNo dose is approved or established for humans, and no human dose-finding study has been published. [1] Ann Clin Lab Sci, 2025 ↗
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- PNC-27 is a 32-amino-acid laboratory peptide that combines part of the p53 protein with a cell-penetrating sequence. It is studied for killing cancer cells in the laboratory and is not a cancer treatment.
- Targets & Selectivity: In laboratory studies it binds HDM-2 protein found on the membrane of cancer cells and forms pores that lyse the cells, while sparing normal cells that lack membrane HDM-2.
- No human clinical trial has been published. Biomedicines 2022: structural and microscopy studies showed PNC-27 binding membrane HDM-2 and forming pores in cancer cells. Ann Clin Lab Sci 2025: it killed squamous cervical cancer cells but not untransformed cervical cells in culture.
- Safety considerations: There are no human safety data. Laboratory selectivity for cancer cells does not establish safety in the body.
? Unknown / Under Ongoing Investigation
- Whether it has any effect or is safe in people is unknown; it must not be presented or used as a cancer treatment.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysPNC-27 is a 32-amino-acid laboratory peptide that combines part of the p53 protein with a cell-penetrating sequence. It is studied for killing cancer cells in the laboratory and is not a cancer treatment.
In laboratory studies it binds HDM-2 protein found on the membrane of cancer cells and forms pores that lyse the cells, while sparing normal cells that lack membrane HDM-2.
No. Not approved by the US FDA or any other regulator; it is a research compound.
No human clinical trial has been published. All published studies are laboratory (cell) studies, including cervical, other solid-tumour and blood cancer cell lines.
No human clinical trial has been published. Biomedicines 2022: structural and microscopy studies showed PNC-27 binding membrane HDM-2 and forming pores in cancer cells. Ann Clin Lab Sci 2025: it killed squamous cervical cancer cells but not untransformed cervical cells in culture.
- HDM-2-targeting peptide PNC-27 kills cervical cancer cells but not normal cervical cells (Ann Clin Lab Sci, 2025-05-01)
- PNC-27, a chimeric p53-penetratin peptide, binds to HDM-2 and induces selective membrane-pore formation leading to cancer cell lysis (Biomedicines, 2022-04-27)
There are no human safety data. Laboratory selectivity for cancer cells does not establish safety in the body.
Whether it has any effect or is safe in people is unknown; it must not be presented or used as a cancer treatment.
No dose is approved or established for humans, and no human dose-finding study has been published.
- HDM-2-targeting peptide PNC-27 kills cervical cancer cells but not normal cervical cells (Ann Clin Lab Sci, 2025-05-01)
There is no approved product label, so no official storage instructions exist.
It is not named individually on the 2026 WADA Prohibited List. Under section S0 (non-approved substances), any pharmacological substance without a current approval by a government health authority for human therapeutic use is prohibited at all times. Athletes should confirm with their national anti-doping organisation.
- WADA Prohibited List (World Anti-Doping Agency)
Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and published studiesHDM-2-targeting peptide PNC-27 kills cervical cancer cells but not normal cervical cells ↗
https://pubmed.ncbi.nlm.nih.gov/40750238/
PNC-27, a chimeric p53-penetratin peptide, binds to HDM-2 and induces selective membrane-pore formation leading to cancer cell lysis ↗
https://pubmed.ncbi.nlm.nih.gov/35625682/